MEDIROM Healthcare Technologies Inc.

MEDIROM Healthcare Technologies Inc.

NNASDAQ:MRM
0.28
USD
+0.00
(+1.16%)
8.14MMarket Cap
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
TTM
Revenue per Share
711.9
810.42
692.92
1,109.16
1,425.77
1,398.45
1,624.92
- -
Basic EPS, GAAP
13.75
3.59
-111.8
-203.13
30.54
23.64
29.13
- -
Free Cash Flow per Basic Share
19.03
-2.41
-97.57
-137.58
-174.72
-318.23
-371.32
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-24.81
126.66
101.87
-42.67
-12.16
43.19
118.11
118.11
Tangible Book Value per Share
-54.41
93.75
50.37
-245.72
-205.33
-244.63
-75.32
-75.32
Basic Weighted Avg Shares
5
5
5
5
5
5
5
5
Sales/Revenue/Turnover
3,433
3,908
3,342
5,410
6,954
6,828
8,299
- -
Operating Margin (%)
3.32
2.02
-15.8
-7.02
1.69
-5.42
0.22
- -
Depreciation Expense
44
46
62
126
184
253
290
- -
Net Income, GAAP
66
17
-539
-991
149
115
149
- -
Effective Tax Rate (%)
27.47
48.76
- -
- -
17.14
- -
- -
- -
Profit Margin (%)
1.93
0.44
-16.14
-18.31
2.14
1.69
1.79
- -
Working Capital
-1,417
-884
-565
-1,814
-1,279
-1,802
-1,475
-1,475
LT Debt
1,667
1,287
1,661
1,875
2,362
2,385
2,052
2,052
Total Equity
-118
600
491
-208
-59
216
1,188
1,188
Return on Invested Capital (%)
- -
0.62
- -
- -
2.75
- -
- -
- -
Return on Capital (%)
- -
0.85
- -
- -
5.46
- -
- -
- -
Return on Common Equity (%)
- -
- -
-98.81
- -
- -
- -
26
- -

Capital Structure

JPY

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
ST Debt
1,264
1,334
1,905
LT Borrowings
1,051
1,011
764
LT Finance Leases
1,335
1,223
1,288
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
5
5
8
Market Capitalization
3,938
3,113
1,279

Working Capital

JPY

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
Total Current Assets
1,759
1,107
2,706
Cash, Cash Equivalents & STI
133
145
336
Accounts Receivable, Net
622
77
1,355
Inventories
140
160
152
Total Current Liabilities
3,561
3,301
4,181
Payables & Accruals
1,414
1,165
1,398
ST Debt
1,264
1,334
1,905
Deferred Revenue
512
306
463

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-49.12%
450.13%
Free Cash Flow
- -
825.8%
22.06%
Net Income, GAAP
- -
-647.04%
28.91%
Sales/Revenue/Turnover
- -
19.13%
21.55%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

JPY

•

in mil. unless spec.

Year

H1
H2
FY
2022
- -
- -
6,954
2023
- -
- -
6,828
2024
- -
- -
8,299

Semi-annual Earnings Per Share

JPY

•

in mil. unless spec.

Year

H1
H2
FY
2022
- -
- -
30.54
2023
- -
- -
23.64
2024
- -
- -
29.13

Semi-annual Dividends Per Share

JPY

•

in mil. unless spec.

Year

H1
H2
FY
2022
- -
- -
- -
2023
- -
- -
- -
2024
- -
- -
- -

Company Description

CEO
Kouji Eguchi
Full Time Employees
- -
Sector
Consumer services
Industry
Other consumer services
Address
2-3-1 Daiba Tokyo TY Japan 135 0091
IPO Date
Dec 29, 2020
Business
MEDIROM Healthcare Technologies Inc. provides holistic health services in Japan through three primary segments: Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty; the Relaxation Salon segment develops, owns, operates, franchises, and supports salons offering finger-pressure style bodywork therapy, stretch therapy, posture and joint alignment, physical therapy elements, anti-fatigue therapy, athletic support therapy, slim-down therapy, and reflexology under the Re.Ra.Ku and Ruam Ruam brands; the Digital Preventative Healthcare segment delivers government-sponsored Specific Health Guidance programs via the Lav on-demand health monitoring smartphone application, MOTHER Bracelet wearable fitness and health tracker, REMONY remote monitoring system, and preventative services utilizing nutritionists and health nurses; and the Luxury Beauty segment manages hair salons under the ZACC brand. The company, founded in 2000 and headquartered at 2-3-1 Daiba, Minato-ku, Tokyo, Japan, primarily serves individual consumers and corporate clients across industries such as nursing care, transportation, construction, manufacturing, and government entities including the Japan Ground Self-Defense Force, with operations concentrated in Japan and aspirations for global expansion as a healthcare general trading company. Recent developments include the acquisition of a rehabilitation business from Y's, Inc. in July 2024, a share transfer agreement in June 2024 to acquire 70% of Japan Gene Medicine Corporation with an option for the remaining 30%, a memorandum of understanding in March 2024 for further share acquisition of Japan Gene Medicine, collaboration with Hakuhodo Inc. in July 2025 to join the World Network proof-of-human protocol co-founded by Sam Altman, adoption of REMONY by the Japan Ground Self-Defense Force and certification by the Ministry of Land, Infrastructure, Transport and Tourism as a fatigue-driving prevention device, surpassing 100 contracted companies and 10,000 supported individuals for Lav Specific Health Guidance services, internal investment in subsidiary MEDIROM MOTHER Labs Inc. at a JPY9 billion Series A valuation, and regaining NASDAQ compliance.

Company News

  • MEDIROM MOTHER Labs Expands Deployment of "REMONY®" Remote Health Monitoring System in JGSDF 8th Division

  • Micromem Technologies Inc. Update on Wearable Sensing Platform for Defence and Security Application Evaluation

  • Micromem Closes Private Placement

  • MEDIROM Group Reports Q1 2026 Results

  • Medirom Healthcare Technologies (NASDAQ:MRM) Shares Down 2.4% – Here’s What Happened

  • MEDIROM Launches Partnership with Tools for Humanity in February; Projects Approximately $39 Million in Income Before Income Taxes Over Two Years Following Expansion to 3,000 Nationwide Locations

  • MEDIROM Forms New Special Mission Team to Drive World ID Adoption Across 3,000 Locations Through Partnership with Tools for Humanity

  • MEDIROM Healthcare Technologies (NYSE:MRM) Shares Down 2.7% – What’s Next?

  • Critical Comparison: Regis (NASDAQ:RGS) and Medirom Healthcare Technologies (NASDAQ:MRM)

  • Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals

  • World, Co-founded by Sam Altman and Alex Blania, Accelerates Expansion in Japan via MEDIROM Collaboration Re.Ra.Ku's “Orb” Authentication Surpasses 20,000 Cumulative Verifications, Doubling in Approximately Two Months

  • Financial Contrast: Medirom Healthcare Technologies (NASDAQ:MRM) and Regis (NASDAQ:RGS)

  • Comparing Medirom Healthcare Technologies (NASDAQ:MRM) and Regis (NASDAQ:RGS)

  • Analyzing Medirom Healthcare Technologies (NASDAQ:MRM) and Regis (NASDAQ:RGS)

  • MEDIROM Partners with World on Technology Envisioned by Sam Altman and Alex Blania: Deploying “Proof of Human” Infrastructure throughout Japan

  • Critical Analysis: Medirom Healthcare Technologies (NASDAQ:MRM) vs. Regis (NASDAQ:RGS)

  • MEDIROM Partners with World

  • Medirom Healthcare Technologies (NASDAQ:MRM) vs. Regis (NASDAQ:RGS) Head-To-Head Analysis

  • Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome

  • MEDIROM MOTHER Labs Inc. Receives Capital Investment from Internal Investors